SCHEMBL6514955

SCHEMBL6514955

Cc1ccc(CNC(=O)c2ccc3[nH]c(=O)n(Cc4ccccc4)c(=O)c3c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.71
TP53 P04637 5/20 0.71
BACE1 P56817 1/20 0.71
RXFP1 Q9HBX9 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.61
MAPK1 P28482 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.59
GLA P06280 1/20 0.59
GAA P10253 1/20 0.59
LMNA P02545 2/20 0.58
HPGD P15428 2/20 0.58
MAPK10 P53779 1/20 0.58
POLB P06746 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
HSD17B10 Q99714 1/20 0.56
HDAC1 Q13547 1/20 0.53
IMPDH2 P12268 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6243893 0.94 MAPT (0.71) MAPTTP53BACE1RXFP1SMN1; SMN2
SCHEMBL6518572 0.91 MAPT (0.68) MAPTTP53BACE1RXFP1SMN1; SMN2
SCHEMBL6471343 0.89 MAPT (0.75) MAPTTP53BACE1SMN1; SMN2L3MBTL1
SCHEMBL7148923 0.84 MAPT (0.68) MAPTTP53BACE1SMN1; SMN2L3MBTL1
SCHEMBL2611397 0.82 KDM4E (0.59) MAPTTP53RXFP1SMN1; SMN2KDM4E
SCHEMBL7023154 0.82 MAPT (0.65) MAPTTP53BACE1SMN1; SMN2L3MBTL1
SCHEMBL6510494 0.82 ALDH1A1 (0.57) MAPTTP53BACE1RXFP1SMN1; SMN2
SCHEMBL7097120 0.80 MAPT (0.62) MAPTTP53BACE1SMN1; SMN2L3MBTL1
SCHEMBL6218489 0.80 HPGD (0.65) MAPTTP53RXFP1SMN1; SMN2KDM4E
SCHEMBL10085009 0.80 KDM4E (0.68) MAPTSMN1; SMN2KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885TP53 4351/4885BACE1 576/4885
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 MAPT 2826/4885TP53 4035/4885BACE1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.